This session is not available for streaming.
Therapeutic Case Report Award
-
2:15-2:30 PM: Dozie Dike, PharmD, BCPP, Clinical Pharmacist Practitioner, Michael E. DeBakey VA Medical Center, Houston, TX
High-Dose Vilazodone for the Treatment of Major Depressive Disorder: A Case Report -
2:30-2:45 PM: Jessica Jones, PharmD, BCPP, Clinical Psychiatric Pharmacist, San Diego County Psychiatric Hospital, San Diego, CA
From Mute to Multilingual: Successful Treatment of Benzodiazepine-Refractory Chronic Catatonia with Memantine
Innovative Practices Award
-
2:45-3:00 PM: Audrey Abelleira, PharmD, BCPP, BCPS, Clinical Pharmacist Practitioner, VISN 1 Clinical Resource Hub, Orange, CT
Integration of a Psychiatric Clinical Pharmacist Practitioner into a Virtual Long-Term Opioid Therapy Reassessment Clinic -
3:00-3:15 PM: Leigh Anne Nelson, PharmD, BCPP, Professor, University of Missouri-Kansas City School of Pharmacy, Kansas City, MO
A Novel Advanced Pharmacy Practice Experience (APPE): Scientific Writing with a Focus in Psychiatric Pharmacotherapy
Original Research Award
-
3:15-3:30 PM: Kevin Kavanagh, PharmD, BCPP, Pharmacist, San Diego County Psychiatric Hospital, San Diego, CA
Do Discharge Medications Prevent Rehospitalization Following Short-Term Crisis Stabilization at a County Psychiatric Hospital? -
3:30-3:45 PM: Aaron Salwan, PharmD, MPH, BCPP, Clinical Pharmacy Specialist, Behavioral Health, Montefiore Nyack Hospital, Nyack, NY
'Tranq': Perceptions of Xylazine and Harm Reduction Practices Among People Receiving Treatment for Substance Use Disorders
Research Trainee Award
-
3:45-4:00 PM: Kristin Manley, PharmD, MHSA – PGY2 Psychiatric Pharmacy Resident, McLean Hospital and Massachusetts General Hospital, Belmont, MA
Psychotropic Stewardship: Review of Antipsychotic Polypharmacy at Discharge from a Free-standing Psychiatric Hospital -
4:00-4:15 PM: Michelle Yang, PharmD, PGY2 Psychiatric Pharmacy Resident, Medical University of South Carolina (MUSC) College of Pharmacy, Charleston, SC
Characterization of Flumazenil Utilization in Electroconvulsive Therapy
AAPP Foundation Strategic Goals Award
-
4:15-4:30 PM: Joseph Cusimano, PharmD, BCPP, Safety Evaluator, Division of Pharmacovigilance-I, U.S. Food and Drug Administration, Silver Spring, MD
Development and Validation of an Instrument to Assess Patient Experience of Pharmacist-led Patient Medication Education Groups -
4:30-4:45 PM: Allison Tiemann, PharmD, PGY2 Pharmacy Resident, Tulsa, OK
Comparison of Pharmacist-Led Outpatient Depression Management to Current Prescriber-Led Depression Management
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.